{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T23:33:32Z","timestamp":1772148812702,"version":"3.50.1"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2020,12,26]],"date-time":"2020-12-26T00:00:00Z","timestamp":1608940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100004785","name":"NordForsk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004785","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014034","name":"Foundation for Research in Rheumatology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014034","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Helsinki University Hospital Institutional grant"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To compare treatment retention and response to secukinumab vs adalimumab, including the other four TNF inhibitors (TNFi) as comparators, in PsA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>All patients with PsA starting secukinumab or a TNFi in 2015\u20132018 were identified in the biologic registers of the Nordic countries. Data on comorbidities were linked from national registers. One-year treatment retention and hazard ratios (HRs) for treatment discontinuation were calculated. The proportion achieving a 6 month 28-joint Disease Activity Index for Psoriatic Arthritis (DAPSA28) remission was determined together with odds ratios (ORs) for remission (logistic regression). Both HRs and ORs were calculated with adalimumab as the reference and adjusted for baseline characteristics and concurrent comorbidities. All analyses were stratified by the line of biologic treatment (first, second, third+).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We identified 6143 patients contributing 8307 treatment courses (secukinumab, 1227; adalimumab, 1367). Secukinumab was rarely used as the first biologic, otherwise baseline characteristics were similar. No clinically significant differences in treatment retention or response rates were observed for secukinumab vs adalimumab. The adjusted HRs for discontinuation per the first, second and third line of treatment were 0.98 (95% CI 0.68, 1.41), 0.94 (0.70, 1.26) and 1.07 (0.84, 1.36), respectively. The ORs for DAPSA28 remission in the first, second and third line of treatment were 0.62 (95% CI 0.30, 1.28), 0.85 (0.41, 1.78) and 0.74 (0.36, 1.51), respectively. In the subset of patients previously failing a TNFi due to ineffectiveness, the results were similar.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>No significant differences in treatment retention or response were observed between secukinumab and adalimumab, regardless of the line of treatment. This suggests that even in patients who have failed a TNFi, choosing either another TNFi or secukinumab may be equally effective.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaa825","type":"journal-article","created":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T16:46:28Z","timestamp":1605890788000},"page":"3635-3645","source":"Crossref","is-referenced-by-count":23,"title":["Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritis"],"prefix":"10.1093","volume":"60","author":[{"given":"Ulf","family":"Lindstr\u00f6m","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bente","family":"Glintborg","sequence":"additional","affiliation":[{"name":"DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet, Copenhagen, Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3817-8288","authenticated-orcid":false,"given":"Daniela","family":"Di Giuseppe","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanja","family":"Schj\u00f8dt J\u00f8rgensen","sequence":"additional","affiliation":[{"name":"Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bjorn","family":"Gudbjornsson","sequence":"additional","affiliation":[{"name":"Centre for Rheumatology Research, University Hospital and Faculty of Medicine, University of Iceland, Reykjavik, Iceland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathrine","family":"Lederballe Gr\u00f8n","sequence":"additional","affiliation":[{"name":"DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5442-902X","authenticated-orcid":false,"given":"Sella","family":"Aarrestad Provan","sequence":"additional","affiliation":[{"name":"Diakonhjemmet Hospital, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Michelsen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway"},{"name":"Division of Rheumatology, Department of Medicine, Hospital of Southern Norway Trust, Kristiansand, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merete","family":"Lund Hetland","sequence":"additional","affiliation":[{"name":"DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet, Copenhagen, Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4915-2924","authenticated-orcid":false,"given":"Johan K","family":"Wallman","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences Lund, Rheumatology, Lund University, Sk\u00e5ne University Hospital, Lund, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Nordstr\u00f6m","sequence":"additional","affiliation":[{"name":"Department of Medicine and rheumatology, Helsinki University and Helsinki University Hospital, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Trokovic","sequence":"additional","affiliation":[{"name":"ROB-FIN, Helsinki University, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thorvardur Jon","family":"Love","sequence":"additional","affiliation":[{"name":"Centre for Rheumatology Research, University Hospital and Faculty of Medicine, University of Iceland, Reykjavik, Iceland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels Steen","family":"Krogh","sequence":"additional","affiliation":[{"name":"Zitelab, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Askling","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lennart T H","family":"Jacobsson","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars Erik","family":"Kristensen","sequence":"additional","affiliation":[{"name":"Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,12,26]]},"reference":[{"key":"2021080220005196100_keaa825-B1","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N Engl J Med"},{"key":"2021080220005196100_keaa825-B2","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/rheumatology\/key075.533","article-title":"Concomitant fibromyalgia complicating chronic inflammatory arthritis: a systematic review and meta-analysis","volume":"57","author":"Duffield","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2021080220005196100_keaa825-B3","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2021080220005196100_keaa825-B4","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N Engl J Med"},{"key":"2021080220005196100_keaa825-B5","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis\u2014results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"key":"2021080220005196100_keaa825-B6","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","article-title":"Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial","volume":"395","author":"McInnes","year":"2020","journal-title":"Lancet"},{"key":"2021080220005196100_keaa825-B7","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","article-title":"A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-na\u00efve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial","volume":"79","author":"Mease","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2021080220005196100_keaa825-B8","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1001\/jama.297.11.1233","article-title":"Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review","volume":"297","author":"Van Spall","year":"2007","journal-title":"JAMA"},{"key":"2021080220005196100_keaa825-B9","first-page":"1068","article-title":"The majority of patients with psoriatic arthritis are not eligible for randomised clinical trials","volume":"36","author":"Runarsdottir","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"2021080220005196100_keaa825-B10","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1080\/03009742.2018.1444199","article-title":"Biological treatment in ankylosing spondylitis in the Nordic countries during 2010\u20132016: a collaboration between five biological registries","volume":"47","author":"Glintborg","year":"2018","journal-title":"Scand J Rheumatol"},{"key":"2021080220005196100_keaa825-B11","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/annrheumdis-2015-207507","article-title":"Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score","volume":"75","author":"Schoels","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2021080220005196100_keaa825-B12","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1136\/annrheumdis-2018-213463","article-title":"Can disease activity in patients with psoriatic arthritis be adequately assessed by a modified Disease Activity index for PSoriatic Arthritis (DAPSA) based on 28 joints?","volume":"77","author":"Michelsen","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2021080220005196100_keaa825-B13","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/art.21570","article-title":"The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden","volume":"54","author":"Kristensen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2021080220005196100_keaa825-B14","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/annrheumdis-2017-212196","article-title":"Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study","volume":"77","author":"Mariette","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2021080220005196100_keaa825-B15","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s40744-018-0106-6","article-title":"Secukinumab versus adalimumab for psoriatic arthritis: comparative effectiveness up to 48 weeks using a matching-adjusted indirect comparison","volume":"5","author":"Nash","year":"2018","journal-title":"Rheumatol Ther"},{"key":"2021080220005196100_keaa825-B16","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s40744-017-0070-6","article-title":"Comparative effectiveness of adalimumab versus secukinumab for the treatment of psoriatic arthritis: a matching-adjusted indirect comparison","volume":"4","author":"Strand","year":"2017","journal-title":"Rheumatol Ther"},{"key":"2021080220005196100_keaa825-B17","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.2217\/cer-2018-0075","article-title":"Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics\/apremilast: a network meta-analysis","volume":"7","author":"McInnes","year":"2018","journal-title":"J Comp Eff Res"},{"key":"2021080220005196100_keaa825-B18","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40744-019-0163-5","article-title":"Efficacy and safety of subcutaneous secukinumab 150 mg with or without loading regimen in psoriatic arthritis: results from the FUTURE 4 study","volume":"6","author":"Kivitz","year":"2019","journal-title":"Rheumatol Ther"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/8\/3635\/39543514\/keaa825.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/8\/3635\/39543514\/keaa825.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T20:15:50Z","timestamp":1627935350000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/8\/3635\/6053174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,26]]},"references-count":18,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,12,26]]},"published-print":{"date-parts":[[2021,8,2]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa825","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,8,1]]},"published":{"date-parts":[[2020,12,26]]}}}